Adjuvant chemoradiotherapy versus adjuvant chemotherapy for patients with N3 gastric cancer after D2/R0 resection: a retrospective study based on propensity score analyses

Meng-Long Zhou,1,2,* Wang Yang,1,2,* Ya-Qi Wang,1,2,* Miao Mo,2,3 Ran Hu,1,2 Yan Wang,1,2 Jia-Ning Yang,1,2 Gui-Chao Li,1,2 Ya-Nong Wang,2,4 Zhen Zhang1,21Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, People’s Republic of China; 2Department of...

Full description

Bibliographic Details
Main Authors: Zhou ML, Yang W, Wang YQ, Mo M, Hu R, Wang Y, Yang JN, Li GC, Wang YN, Zhang Z
Format: Article
Language:English
Published: Dove Medical Press 2019-05-01
Series:Cancer Management and Research
Subjects:
Online Access:https://www.dovepress.com/adjuvant-chemoradiotherapy-versus-adjuvant-chemotherapy-for-patients-w-peer-reviewed-article-CMAR
id doaj-5218b7c267ea47ae8f2c4b691c224b54
record_format Article
spelling doaj-5218b7c267ea47ae8f2c4b691c224b542020-11-24T21:30:49ZengDove Medical PressCancer Management and Research1179-13222019-05-01Volume 114855487046117Adjuvant chemoradiotherapy versus adjuvant chemotherapy for patients with N3 gastric cancer after D2/R0 resection: a retrospective study based on propensity score analysesZhou MLYang WWang YQMo MHu RWang YYang JNLi GCWang YNZhang ZMeng-Long Zhou,1,2,* Wang Yang,1,2,* Ya-Qi Wang,1,2,* Miao Mo,2,3 Ran Hu,1,2 Yan Wang,1,2 Jia-Ning Yang,1,2 Gui-Chao Li,1,2 Ya-Nong Wang,2,4 Zhen Zhang1,21Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People’s Republic of China; 3Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Shanghai, 200032, People’s Republic of China; 4Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, People’s Republic of China*These authors contributed equally to this workPurpose: N3 gastric cancer (GC) is characterized by a heavy burden of lymph node metastasis and a high postoperative recurrence rate. The role of radiotherapy in this group of patients remains undetermined. The purpose of this study was to compare the effectiveness of adjuvant chemoradiotherapy (CRT) and adjuvant chemotherapy (ChT) for N3 GC after D2/R0 resection.Patients and methods: From January 2004 to December 2015, patients with N3 GC in the database of Fudan University Shanghai Cancer Center were retrospectively reviewed. The eligible patients were enrolled in an adjuvant CRT group and an adjuvant ChT group. Four different methods based on a propensity score model were used to balance the baseline characteristics. Then, survival analyses between the two groups were performed in addition to patterns of recurrence and subgroup analyses.Results: In total, 175 and 365 eligible patients were enrolled into the CRT and ChT groups, respectively. After balancing, the disease-free survival (DFS) of patients in the CRT group was significantly better than that of patients in the ChT group (p=0.021). Subgroup analyses showed that patients with N3a GC benefitted from adjuvant CRT.Conclusion: Compared with adjuvant ChT, adjuvant CRT can further improve the DFS of patients with N3 GC after D2/R0 resection. Patients with lymph node metastases should be further stratified when selecting patients for adjuvant CRT.Keywords: stomach neoplasms, gastrectomy, chemoradiation, propensity score, survival analysis  https://www.dovepress.com/adjuvant-chemoradiotherapy-versus-adjuvant-chemotherapy-for-patients-w-peer-reviewed-article-CMARstomach neoplasmsgastrectomychemoradiationpropensity scoresurvival analysis
collection DOAJ
language English
format Article
sources DOAJ
author Zhou ML
Yang W
Wang YQ
Mo M
Hu R
Wang Y
Yang JN
Li GC
Wang YN
Zhang Z
spellingShingle Zhou ML
Yang W
Wang YQ
Mo M
Hu R
Wang Y
Yang JN
Li GC
Wang YN
Zhang Z
Adjuvant chemoradiotherapy versus adjuvant chemotherapy for patients with N3 gastric cancer after D2/R0 resection: a retrospective study based on propensity score analyses
Cancer Management and Research
stomach neoplasms
gastrectomy
chemoradiation
propensity score
survival analysis
author_facet Zhou ML
Yang W
Wang YQ
Mo M
Hu R
Wang Y
Yang JN
Li GC
Wang YN
Zhang Z
author_sort Zhou ML
title Adjuvant chemoradiotherapy versus adjuvant chemotherapy for patients with N3 gastric cancer after D2/R0 resection: a retrospective study based on propensity score analyses
title_short Adjuvant chemoradiotherapy versus adjuvant chemotherapy for patients with N3 gastric cancer after D2/R0 resection: a retrospective study based on propensity score analyses
title_full Adjuvant chemoradiotherapy versus adjuvant chemotherapy for patients with N3 gastric cancer after D2/R0 resection: a retrospective study based on propensity score analyses
title_fullStr Adjuvant chemoradiotherapy versus adjuvant chemotherapy for patients with N3 gastric cancer after D2/R0 resection: a retrospective study based on propensity score analyses
title_full_unstemmed Adjuvant chemoradiotherapy versus adjuvant chemotherapy for patients with N3 gastric cancer after D2/R0 resection: a retrospective study based on propensity score analyses
title_sort adjuvant chemoradiotherapy versus adjuvant chemotherapy for patients with n3 gastric cancer after d2/r0 resection: a retrospective study based on propensity score analyses
publisher Dove Medical Press
series Cancer Management and Research
issn 1179-1322
publishDate 2019-05-01
description Meng-Long Zhou,1,2,* Wang Yang,1,2,* Ya-Qi Wang,1,2,* Miao Mo,2,3 Ran Hu,1,2 Yan Wang,1,2 Jia-Ning Yang,1,2 Gui-Chao Li,1,2 Ya-Nong Wang,2,4 Zhen Zhang1,21Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People’s Republic of China; 3Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Shanghai, 200032, People’s Republic of China; 4Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, People’s Republic of China*These authors contributed equally to this workPurpose: N3 gastric cancer (GC) is characterized by a heavy burden of lymph node metastasis and a high postoperative recurrence rate. The role of radiotherapy in this group of patients remains undetermined. The purpose of this study was to compare the effectiveness of adjuvant chemoradiotherapy (CRT) and adjuvant chemotherapy (ChT) for N3 GC after D2/R0 resection.Patients and methods: From January 2004 to December 2015, patients with N3 GC in the database of Fudan University Shanghai Cancer Center were retrospectively reviewed. The eligible patients were enrolled in an adjuvant CRT group and an adjuvant ChT group. Four different methods based on a propensity score model were used to balance the baseline characteristics. Then, survival analyses between the two groups were performed in addition to patterns of recurrence and subgroup analyses.Results: In total, 175 and 365 eligible patients were enrolled into the CRT and ChT groups, respectively. After balancing, the disease-free survival (DFS) of patients in the CRT group was significantly better than that of patients in the ChT group (p=0.021). Subgroup analyses showed that patients with N3a GC benefitted from adjuvant CRT.Conclusion: Compared with adjuvant ChT, adjuvant CRT can further improve the DFS of patients with N3 GC after D2/R0 resection. Patients with lymph node metastases should be further stratified when selecting patients for adjuvant CRT.Keywords: stomach neoplasms, gastrectomy, chemoradiation, propensity score, survival analysis  
topic stomach neoplasms
gastrectomy
chemoradiation
propensity score
survival analysis
url https://www.dovepress.com/adjuvant-chemoradiotherapy-versus-adjuvant-chemotherapy-for-patients-w-peer-reviewed-article-CMAR
work_keys_str_mv AT zhouml adjuvantchemoradiotherapyversusadjuvantchemotherapyforpatientswithn3gastriccancerafterd2r0resectionaretrospectivestudybasedonpropensityscoreanalyses
AT yangw adjuvantchemoradiotherapyversusadjuvantchemotherapyforpatientswithn3gastriccancerafterd2r0resectionaretrospectivestudybasedonpropensityscoreanalyses
AT wangyq adjuvantchemoradiotherapyversusadjuvantchemotherapyforpatientswithn3gastriccancerafterd2r0resectionaretrospectivestudybasedonpropensityscoreanalyses
AT mom adjuvantchemoradiotherapyversusadjuvantchemotherapyforpatientswithn3gastriccancerafterd2r0resectionaretrospectivestudybasedonpropensityscoreanalyses
AT hur adjuvantchemoradiotherapyversusadjuvantchemotherapyforpatientswithn3gastriccancerafterd2r0resectionaretrospectivestudybasedonpropensityscoreanalyses
AT wangy adjuvantchemoradiotherapyversusadjuvantchemotherapyforpatientswithn3gastriccancerafterd2r0resectionaretrospectivestudybasedonpropensityscoreanalyses
AT yangjn adjuvantchemoradiotherapyversusadjuvantchemotherapyforpatientswithn3gastriccancerafterd2r0resectionaretrospectivestudybasedonpropensityscoreanalyses
AT ligc adjuvantchemoradiotherapyversusadjuvantchemotherapyforpatientswithn3gastriccancerafterd2r0resectionaretrospectivestudybasedonpropensityscoreanalyses
AT wangyn adjuvantchemoradiotherapyversusadjuvantchemotherapyforpatientswithn3gastriccancerafterd2r0resectionaretrospectivestudybasedonpropensityscoreanalyses
AT zhangz adjuvantchemoradiotherapyversusadjuvantchemotherapyforpatientswithn3gastriccancerafterd2r0resectionaretrospectivestudybasedonpropensityscoreanalyses
_version_ 1725961647230550016